Document:

Amendment to Service Agreement

 EXHIBIT 10.2 
 AMENDMENT TO SERVICE AGREEMENT 
 This amendment is entered into with an effective date of
January 1, 2006, between Wisconsin Dental Group, S.C., a Wisconsin service corporation (“Provider”), and American Dental Partners of Wisconsin, LLC, a Delaware limited liability company (“Service Company”), who hereby agree
as follows: 
 1. Definitions. All capitalized terms used in this amendment which are not otherwise defined herein shall have the
respective meanings given to those terms in the Amended and Restated Service Agreement dated January 1, 1999 (the “Service Agreement”). 
 2. Service Fee. The percentage set forth in the last sentence of Section 7.3 of the Service Agreement is hereby changed from 8% to 9%. 
 3. Provider Retained Earnings. The percentage set forth in Section 7.8 of the Service Agreement is hereby changed from 92% to 91%.

 4. Effective Date. This amendment shall be effective as of the date first set forth above. 
 5. Construction. This is an amendment to and a part of the Service Agreement. In the event of any inconsistency between the provisions of the
Service Agreement and the provisions of this amendment, the provisions of this amendment shall control prospectively from the effective date of this amendment. Except as modified by this amendment, the Service Agreement shall continue in full force
and effect without change. 
  

									
	 WISCONSIN DENTAL GROUP, S.C.
	 		 	 American Dental Partners, of Wisconsin, LLC

					
	By:	 	 /s/ Robert Trettin
	 		 	 By:
	 	 /s/ Ian H. Brock

		 	 Robert Trettin, D.D.S., President
	 		 	 Its:
	 	 Vice President

	 Date of Execution:  April 28,
2006                                        
    
	 		 	 Date of Execution:  May 8,
2006                                        
        

  

 1Untitled Document

EXECUTION COPY 

GENTA
INCORPORATED  

Two Connell Drive  

Berkeley Heights, NJ 07922 

Dated as of
January 1, 2006 

Dr. Raymond P.
Warrell, Jr.  

Two Connell Drive  

Berkeley Heights, NJ 07922 

Dear Dr.
Warrell: 

          We
are pleased that you are willing to  continue to serve as Chief Executive Officer, and
Chairman  of the Board of Directors (the “Board”), of Genta  Incorporated, a
Delaware corporation (together with its  successors and assigns, the “Company”).
Accordingly, we  would like to offer you continued employment on the terms  set forth in
this letter agreement (this “Agreement”), which  upon countersignature by you
shall become a binding  agreement between you and the Company (each, a “Party”). 

     1. Employment; Duties. 

          (a)
As of January 1, 2006 (the “Effective Date”), the  Company hereby engages and
employs you, and you hereby  accept engagement and employment, as an employee of the
Company for the duration of the “Term” (as defined in  Section 2 below). 

          (b)
During the Term, you shall serve as Chief Executive  Officer of the Company and (subject
to re-election to the  Board by the shareholders of the Company) as a member of,  and
Chairman of, the Board; shall have all authorities,  duties and responsibilities
customarily exercised by an  individual serving in those positions at an entity of the
size and nature of the Company; shall be assigned no duties  or responsibilities that are
materially inconsistent with,  or that materially impair your ability to discharge, the
foregoing duties and responsibilities; and shall, in your  capacity as Chief Executive
Officer of the Company, report  solely and directly to the Board.  During the Term, your
principal office, and principal place of employment, shall  be at the Company’s
principal executive offices, but you  shall perform your duties hereunder at such places
as shall  be necessary according to the needs, business and  opportunities of the
Company; provided that you acknowledge  and agree that the performance of your duties
hereunder may  require significant domestic and international travel by  you. 

          (c)
During the Term, you shall devote substantially all  of your business time and efforts to
the proper discharge of  your duties hereunder.  You shall not, directly or  indirectly,
on a full-time, part-time, temporary, consulting  or any other basis, work for, or
provide services to, any  other person, firm, corporation, partnership, joint venture  or
other business entity that would  

conflict,
either  directly or indirectly, with your duties hereunder, without  the prior written
consent of a representative of the Company  specifically authorized by the Board or by
the Compensation  Committee of the Board (the “Committee”) to give such
consent, provided, however, that nothing shall preclude you  from (i) serving on the
boards of a reasonable number of  trade associations and/or charitable organizations, on
the  boards of any for-profit enterprises on which you are  serving as of the Effective
Date, and on the boards of such  additional for-profit enterprises as the Board may
specifically approve (which approval shall not be  unreasonably withheld or delayed),
(ii) engaging in  charitable activities and community affairs, and (iii)  managing your
personal investments and affairs; so long as  such activities do not, either individually
or in the  aggregate, interfere with your ability to perform, or  otherwise conflict
with, your duties hereunder. 

     2.   Term.  The Company hereby employs you under this  Agreement, and you hereby accept such
employment, for the  Term.  The Term shall commence as of the Effective Date and  shall
end on December 31, 2008; provided, however, that the  Term shall thereafter be
automatically and indefinitely  extended for additional one-year periods unless, (i) at
least six months prior to the then-scheduled date of  expiration of the Term (the
“Scheduled Expiration Date”),  the Company gives notice to you that it is
electing not to  so extend the Term or you give notice to the Company that  you are
electing not to so extend the Term, provided that  the Company shall be deemed to have
timely given you notice  of non-extension if it gives you such notice within 45 days
after receiving notice from you that the Scheduled  Expiration Date is to occur (such
notice to be provided by  you no earlier than eight months prior to the Scheduled
Expiration Date), or (ii) you fail to notify the Company of  the Scheduled Expiration
Date at least 90 days prior to the  Scheduled Expiration Date, in which event the Term
shall end  on the Scheduled Expiration Date, and shall be deemed for  all purposes to
have ended pursuant to timely notice of  non-extension from you to the Company pursuant
to clause  (i), unless the Parties agree otherwise in writing.  Notwithstanding the
foregoing, the Term may be earlier  terminated in strict accordance with the provisions
of  Section 9. 

     3.
Compensation and Benefits. 

          (a)
            Base Salary.  Commencing as of the Effective Date,  you shall receive a base salary (“Base
Salary”) of $460,000  per annum during the Term, payable in accordance with the
Company’s standard payroll practices but no less frequently  than monthly.  Your
Base Salary shall be reviewed no less  frequently than annually during the Term (after
calendar  year 2006) for discretionary increase, effective January 1  of the year of
increase, and shall in any event be increased  as of January 1, 2007 and as of each
subsequent January 1  during the Term by a percentage equal to at least the  percentage
increase in the CPI (All Urban Consumers) for the  calendar year preceding the year of
increase.  Your Base  Salary shall not be decreased at any time, or for any  purpose,
during the Term (including, without limitation, for  the purpose of determining benefits
under Section 10)  without your prior written consent. 

          (b)
            Annual Bonus.  You shall receive a cash bonus (a  “Bonus”) with respect to each
calendar year that ends during  the Term, ranging from 0% to 60% of you Base Salary, to
the  extent that the Company attains goals and objectives for  such year that have been
mutually  

2 

agreed upon by
you and the  Committee, in accordance with this Section 3(b). You and the  Committee
shall use your best reasonable efforts to ensure  that such goals and objectives are
agreed upon prior to  March 30 of the calendar year to which a Bonus relates.  Except to
the extent otherwise agreed by you and the  Committee, your potential Bonus shall range
from 0% of your  annualized Base Salary to 60% of your annualized Base  Salary, with a
“target” Bonus of 40% of your annualized Base  Salary if agreed-upon goals and
objectives are achieved for  the calendar year.  Except to the extent otherwise agreed by
you and the Committee, all goals and objectives will  represent significant value
creation activities for the  Company and “stretch target” goals and objectives
will  represent extraordinary performance and achievement.  “Stretch target” performance
against the agreed-upon goals  and objectives for such year shall entitle you to a Bonus
for such year equal to at least 60% of your annualized Base  Salary for such year.
Lesser amounts may be awarded for  performance below “target”, and intermediate
amounts may be  awarded for performance between “target” and “stretch
target”.  The extent to which the agreed-upon goals and  objectives are attained
shall be determined by the Committee  reasonably and in good faith, in consultation with
you, as  soon as reasonably practicable after the end of the calendar  year to which the
Bonus at issue relates.  The Bonus earned  by you for a calendar year shall be paid to
you promptly  after its amount has been determined, and in no event later  than the
earlier of (x) the date that other senior  executives of the Company receive their annual
bonuses for  such year and (y) March 15 of the year following such year. 

          (c)
            Withholding.  The Company shall withhold all  applicable Federal, state and local taxes,
social security  and workers’ compensation contributions and other amounts as  may
be required by law or agreed upon by the Parties with  respect to compensation payable to
you pursuant to this  Agreement. 

          (d)
            Initial Option Grant.  As of the date you execute  this Agreement, the Company shall
grant you an option to  acquire 1,000,000 shares of its Common Stock, at an exercise
price per share equal to the Fair Market Value of a share of  such Common Stock on such
date, and otherwise on the terms  and conditions set forth in the Stock Option Agreement
that  is attached hereto as Exhibit A, which Stock Option  Agreement shall be fully
executed by the Parties promptly  upon full execution of this Agreement.  For purposes of
this  Agreement, “Fair Market Value” shall be determined as  provided in the
Company’s 1998 Stock Incentive Plan, as  amended through the Effective Date (the
“1998 Plan”). 

          (e)
            Annual Stock Option Awards.  Each calendar year  that commences during the Term, you
shall be granted, no  later than the date that your Bonus (if any) for the prior
calendar year is due to be paid pursuant to Section 3(b) and  provided that you
remain employed hereunder on the date of  grant, a stock option award for the purchase of
a number of  shares of the Company’s Common Stock as computed pursuant to  this
Section 3(e)(with the number and type of securities  equitably adjusted for stock splits,
reverse stock splits,  stock reclassifications, mergers, recapitalizations, etc.,  that
occur between the Effective Date and the date of grant  of the stock option) (“a
Section 3(e) Stock Option”).  The  “target” number  of  shares subject to
a “Section 3(e) Stock  Option” to be awarded each calendar year will be 150,000
shares, and the potential number of  of shares subject to  each Section 3(e) Stock Option
award for a calendar year  shall range from  0 shares to 225,000 shares.  The number of
shares subject to a Section 3(e) Stock Option to be awarded  to you within such range in
a calendar year shall be based  on your  

3 

achievement of
Company goals and objectives, and  will be at the sole discretion of the Board or the
Committee.  Each Section 3(e) Stock Option shall have a  ten-year term; shall have an
exercise price per share equal  to Fair Market Value on the date of grant; shall fully
vest,  and become fully exercisable, upon the occurrence of a  “Trigger Event” (as
such term is defined in Section 2(d) of  the Stock Option Agreement that is attached
hereto as  Exhibit A); and shall be evidenced by a stock option  agreement that: (x)
provides for treatment as an Incentive  Stock Option to the extent you so elect prior to
the date of  grant and to the extent possible consistent with the terms  of this
Agreement and of your other then-outstanding stock  option grants, (y) otherwise contains
terms and provisions  no less favorable to you in any respect than those applying  to
corresponding grants to other senior executives of the  Company, and (z) unless the
Committee specifically  determines otherwise, the terms and provisions of each  annual
grant shall be identical to those applying to  corresponding grants to other senior
executives of the  Company.  All securities delivered on any exercise of any  stock
option granted pursuant to this Section 3(e) or  Section 3(f) below shall be fully
registered, and publicly  tradable, to the extent that any other securities of the  same
class are then fully registered and publicly tradable;  provided, however, that in no
event shall the Company be  required to prepare and file a Form S-3 reoffer prospectus
with respect to any shares that you receive in connection  with your exercise of any
stock option granted pursuant to  this Section 3(e) or Section 3(f). 

          (f)
            Trigger Event Stock Option Award.  In addition, if  a Trigger Event occurs during the
Term or within 12 months  thereafter, you shall be entitled to receive, as promptly
as  reasonably practicable following the occurrence of such  Trigger Event, any Section 3(e)
Stock Option that you would  have been entitled to receive in respect of the calendar
year in which such Trigger Event occurs (assuming continued  employment hereunder through
the end of such calendar year  and attainment of “target” levels of performance
on all  annual Bonus goals and objectives for such year).  Any such  stock option shall:
(i) have an exercise price per share  equal to Fair Market Value on the day immediately
prior to  the day that such Trigger Event occurs; (ii) be fully  vested, and fully
exercisable, upon grant; (iii) otherwise  be on terms and conditions no less favorable to
you than the  terms and conditions that would have applied if the grant  had been made
under Section 3(e) above; and (iv) be granted  in lieu of the Section 3(e) Stock Option
that you would  otherwise have been entitled to receive in respect of the  calendar year
in question. 

          (g)
Restrictions on Sale of Option Stock. 

               (i)
Unless otherwise agreed to in writing by a  representative of the Company expressly
authorized to act by  the Board or the Committee, you agree not to sell on any  single
day, after the Term, a number of Covered Option  Shares that exceeds 3% of the trading
volume of the Common  Stock of the Company on the immediately preceding trading  day as
reported by the Nasdaq National Market or on such  other exchange or market system which
provides the primary  trading market for the Common Stock of the Company at the
applicable time (a “Public Market”).  For purposes of this  Agreement, the term
“Covered Option Share” shall mean any  share of Common Stock of the Company
acquired on any  exercise of the stock option granted pursuant to Section  3(d) above. 

               (ii)
Except as provided in Section 3(g)(i) above or as  otherwise agreed to in writing by a
representative of the  Company expressly authorized to act by the Board or the 

4 

Committee, you
agree that you will not, either during or  after the Term: (x) offer, pledge, sell,
contract to sell,  sell any option or contract to purchase, purchase any option  or
contract to sell, grant any option, right or warrant to  purchase, lend, or otherwise
transfer or dispose of,  directly or indirectly, any Covered Option Share or any
securities convertible into or exercisable or exchangeable  for any Covered Option Share
or (y) enter into any swap or  other arrangement that transfers to another Person (as
defined in Section 3(q) below), in whole or in part, any of  the economic consequences of
ownership of any Covered Option  Share, whether any such transaction described in clause
(x)  or (y) above is to be settled by delivery of Covered Option  Shares or such other
securities, in cash or otherwise;  provided that this Section 3(g)(ii) shall not apply to
any  pledge of Covered Option Shares in connection with payment  of the purchase price of
Covered Option Shares pursuant to  any exercise of the stock option granted pursuant to
Sections 3(d) above, so long as the pledgee agrees that no  sale of Covered Option Shares
by such pledgee on any day,  when added to sales of Covered Option Shares by you on such
day, may exceed the aggregate numerical limit imposed by  Section 3(g)(i) above. 

               (iii)
All sales of Covered Option Shares by you, and by  any pledgee referred to in the proviso
to Section 3(g)(ii),  shall be executed through Merrill Lynch or such other broker  as
the Company may from time to time reasonably designate on  written notice to you. 

               (iv)
The restrictions contained in Sections 3(g)(i),  3(g)(ii) and 3(g)(iii) shall expire on
the earlier of the  second anniversary of the “Termination Date” (as defined in
Section 10(a)(i) below) and ten trading days prior to the  date that Common Stock of the
Company ceases to be traded on  any Public Market. 

          (h)
            Additional Awards.  In addition to the minimum cash  and equity awards required under
Sections 3(b) through 3(f)  above, the Company may from time to time grant you
additional cash, stock option, equity and/or other long-term  incentive awards, in the
sole discretion of the Board or the  Committee. 

          (i) Business Expenses.  The Company shall reimburse you  for all travel, business
entertainment and other business  expenses reasonably incurred by you in connection with
the  performance of your duties under this Agreement.  Such  reimbursement shall be made
by the Company promptly upon  submission by you of appropriate documentation in
accordance  with the Company’s standard procedures. 

          (j)
            Vacation.  You shall be entitled during the Term to  four weeks’ vacation per
calendar year.  You may “carry  over” up to four weeks of accrued but unused
vacation from  year-to-year. 

          (k) Supplemental Life Insurance.  During the Term and  in addition to any life insurance
coverage provided under  Section 3(m) below, the Company shall pay the premiums on a
term life insurance policy in your name and on your behalf  in a principal amount of not
less than $3,250,000 and with  the proceeds payable as you direct; provided that such
premiums do not exceed $10,000 annually, in which event the  Company shall purchase as
much coverage for you as it can  acquire for $10,000 annually. 

5 

          (l)
            Supplemental Disability Insurance.  During the Term  and in addition to any disability
insurance coverage  provided under Section 3(m) below, the Company shall provide  you
with as much disability insurance coverage, acceptable  to you, as it can obtain at a
cost to the Company (beyond  costs incurred by the Company under Section 3(m) below) of
$15,000 annually. 

          (m)
            Employee Benefits.  During the Term, you shall be  entitled to participate in any and all
medical insurance,  dental insurance, group health, disability insurance, life
insurance, retirement, pension, savings, income deferral,  fringe benefit, and other
benefit and perquisite plans,  programs and arrangements that are made generally
available  to senior executives of the Company, in each case on terms  and conditions no
less favorable to you than those applying  to other senior executives of the Company
generally.  For  avoidance of doubt, the Company, in its sole discretion, may  at any
time amend or terminate any such plan, program or  arrangement. 

          (n)
            D&O Insurance.  A directors' and officers'  liability insurance policy (or policies)
shall be kept in  place, during the Term and for six years thereafter,  providing
coverage that is no less favorable to you in any  respect (including, without limitation,
with respect to  scope, exclusions, amounts and deductibles) than the  coverage then
being provided to any other present or former  officer or director of the Company. 

          (o)
            Automobile.  During the Term, the Company shall  provide you with a car or car allowance
in an amount not to  exceed $500 per month, which allowance shall be paid in  appropriate
pro rata amounts at the same time Base Salary is  paid unless the Company pays all
related expenses directly. 

          (p)  Medical Malpractice Insurance.  During the Term,  the Company shall pay the premiums on a
medical malpractice  insurance policy in your name and on your behalf in the  principal
amount of not less than $1,000,000; provided that  such premiums do not exceed $25,000
annually, in which event  the Company shall provide you with as much medical  malpractice
insurance coverage, acceptable to you, as it can  obtain at a cost to the Company of
$25,000 annually. 

          (q)  Indemnification.  If you are made a party, are  threatened to be made a party, or
reasonably anticipate  being made a party, to any Proceeding by reason of the fact  that
you are or were a director, officer, member, employee,  agent, manager, trustee,
consultant or representative of the  Company or any of its Affiliates or are or were
serving at  the request of the Company or any of its Affiliates, or in  connection with
your service hereunder, as a director,  officer, member, employee, agent, manager,
trustee,  consultant or representative of another Person, or if any  Claim is made, is
threatened to be made, or is reasonably  anticipated to be made, that arises out of or
relates to  your service in any of the foregoing capacities, then you  shall promptly be
indemnified and held harmless to the  fullest extent permitted or authorized by the
Certificate of  Incorporation or Bylaws of the Company, or if greater, by  applicable
law, against any and all costs, expenses,  liabilities and losses (including, without
limitation,  attorneys' and other professional fees and charges,  judgments, interest,
expenses of investigation, penalties,  fines, ERISA excise taxes or penalties and amounts
paid or  to be paid in settlement) incurred or suffered by you in  connection therewith
or in connection with seeking to  enforce your rights  

6 

under this
Section 3(q), and such  indemnification shall continue even if you have ceased to be
a director, officer, member, employee, agent, manager,  trustee, consultant or
representative of the Company or  other Person and shall inure to the benefit of your
heirs,  executors and administrators.  You shall be entitled to  prompt advancement of
any and all costs and expenses  (including, without limitation, attorneys’ and other
professional fees and charges) incurred by you in connection  with any such Proceeding or
Claim, or in connection with  seeking to enforce your rights under this Section 3(q), any
such advancement to be made within 15 days after you give  written notice, supported by
reasonable documentation,  requesting such advancement.  Such notice shall include, to
the extent required by applicable law, an undertaking by you  to repay the amount
advanced if you are ultimately  determined not to be entitled to indemnification against
such costs and expenses.  Nothing in this Agreement shall  operate to limit or extinguish
any right to indemnification,  advancement of expenses, or contribution that you would
otherwise have (including, without limitation, by agreement  or under applicable law or
under the Company’s Certificate  of Incorporation).  For purposes of this Agreement,
the  following terms shall have the following meanings:  “Affiliate” of a
Person shall mean any Person that directly  or indirectly controls, is controlled by, or
is under common  control with, such Person; “Claim” shall mean any claim,
demand, request, investigation, dispute, controversy,  threat, discovery request, or
request for testimony or  information; “Person” shall mean any individual,
corporation, partnership, limited liability company, joint  venture, trust, estate,
board, committee, agency, body,  employee benefit plan, or other person or entity; and
“Proceeding” shall mean any threatened or actual action, suit  or proceeding,
whether civil, criminal, administrative,  investigative, appellate, formal, informal or
other.  Notwithstanding the above, this Section 3(q) shall not be  effective unless and
until approved by the Board, which  approval the Committee has agreed to promptly seek. 

          (r)
Golden Parachute Tax. 

               (i)
If the aggregate of all amounts and benefits due to  you, under this Agreement or any
other plan, program,  agreement or arrangement of the Company or any of its  Affiliates,
which, if received by you in full, would  constitute “parachute payments” as
such term is defined in  and under Section 280G of the Code (collectively, “Change
in  Control Benefits”), reduced by all Federal, state and local  taxes applicable
thereto, including the excise tax imposed  pursuant to Section 4999 of the Code, is less
than the  amount you would receive, after taxes, if you received  aggregate Change in
Control Benefits equal to only three  times your “base amount”, as defined in
and determined under  Section 280G of the Code, less $1.00, then such cash Change  in
Control Benefits as you shall select shall be reduced or  eliminated to the extent
necessary so that the Change in  Control Benefits received by you will not constitute
parachute payments (provided that reduction in such cash  Change in Control Benefits can
achieve this objective).  The  determinations with respect to this Section 3(r)(i) shall
be  made by an independent auditor (the “Auditor”) paid by the  Company.  The
Auditor shall be the Company’s regular  independent auditor unless you reasonably
object to the use  of that firm, in which event the Auditor shall be a
nationally-recognized United States public accounting firm  chosen by the Company and
approved by you (which approval  shall not be unreasonably withheld or delayed).  For
purposes of this Agreement, the term “Code” shall mean the  Internal Revenue
Code of 1986, as amended, and any reference  to a particular section of the Code shall
include any  provision that modifies, replaces or supersedes such section. 

7 

               (ii)
It is possible that after the determinations and  selections made pursuant to Section
3(r)(i) you will receive  Change in Control Benefits that are, in the aggregate,  either
more or less than the limitations provided in Section  3(r)(i) above (hereafter referred
to as an “Excess Payment” or “Underpayment”, respectively).  If it is
established,  pursuant to a final determination of a court or an Internal  Revenue
Service proceeding that has been finally and  conclusively resolved, that an Excess
Payment has been made,  then you shall refund the Excess Payment to the Company  promptly
on demand, together with an additional payment in  an amount equal to the product
obtained by multiplying the  Excess Payment times the applicable annual federal rate (as
determined in and under Section 1274(d) of the Code) times a  fraction whose numerator is
the number of days elapsed from  the date of your receipt of such Excess Payment through
the  date of such refund and whose denominator is 365.  In the  event that it is
determined (x) by arbitration under Section  12 below, (y) by a court of competent
jurisdiction, or (z)  by the Auditor upon request by you or the Company, that an
Underpayment has occurred, the Company shall pay an amount  equal to the Underpayment to
you within 10 days of such  determination together with an additional payment in an
amount equal to the product obtained by multiplying the  Underpayment times the
applicable annual federal rate (as  determined in and under Section 1274(d) of the Code)
times a  fraction whose numerator is the number of days elapsed from  the date of the
Underpayment through the date of such  payment and whose denominator is 365.  

          (s)
            Attorneys’ Fees. The Company shall pay attorney’s  fees reasonably incurred by
you in connection with  negotiating, documenting and implementing the arrangements  set
forth in this Agreement in an amount not to exceed  $20,000 and will treat such payments
as a “working condition  fringe” as defined in Section 132(d) of the Code. 

     4.
Representations. 

          (a)
            The Company’s Representations.  The Company  represents and warrants that: (i) it is
fully authorized by  action of the Board and the Committee (and of any other  Person
whose action is required) to enter into this  Agreement and to perform its obligations
under it; (ii) the  execution, delivery and performance of this Agreement by it  does not
violate any applicable law, regulation, order,  judgment or decree or any agreement,
arrangement, plan or  corporate governance document to which it is a party or by  which
it is bound; and (iii) upon the execution and delivery  of this Agreement by the Parties,
this Agreement shall be a  valid and binding obligation of the Company, enforceable
against it in accordance with its terms, except to the  extent that enforceability may be
limited by applicable  bankruptcy, insolvency or similar laws affecting the  enforcement
of creditors’ rights generally. 

          (b)
            Your Representations.  You represent and warrant  that: (i) delivery and performance of
this Agreement by you  does not violate any applicable law, regulation, order,  judgment
or decree or any agreement to which you are a party  or by which you are bound; and (ii) upon the execution and  delivery of this Agreement by the Parties, this Agreement  shall
be a valid and binding obligation of you, enforceable  against you in accordance with its
terms, except to the  extent that enforceability may be limited by applicable
bankruptcy, insolvency or similar laws affecting the  enforcement of creditors’ rights
generally. 

8 

     5.
Non-competition and Non-solicitation. 

          (a)
You understand and recognize that your services to  the Company are special and unique
and you agree that,  during the Term, and, except as provided below, for two  years
thereafter, you shall not, other than in connection  with performing services for the
Company (or any of its  Affiliates) or with the prior written consent of a
representative of the Company specifically authorized by the  Board or the Committee to
give such consent, directly or  indirectly on behalf of yourself or any Person, enter
into,  or engage in, any business that competes, or is actively  planning to compete,
directly and materially with the  Company with respect to any technology or service of,
or any  product manufactured or distributed by, the Company or in  which the Company has
intellectual property rights (except  as provided below, a “Conflicting Field”),
either as an  individual for your own account, or as a partner, joint  venturer,
executive, agent, consultant, salesperson,  officer, director or shareholder of such a
Person (a  “Competitor”); provided, however, that: (i) following any
termination of your employment hereunder, “Conflicting  Field” shall refer only
to the field of using antisense  technology as therapy for cancer as its primary
business;  (ii) subject to the provisions of Section 1(c) above,  nothing in this
Agreement shall preclude you from accepting  employment with, or providing services for,
any Person that  competes, or is actively planning to compete, with the  Company in a
Conflicting Field so long as (x) you work  solely in a subsidiary, division, or other
distinct unit of  such Person that carries on a bona fide business that does  not
compete, and is not actively planning to compete, with  the Company in a Conflicting
Field or (y) you serve as a  member of a board of directors (and not as an employee) and
your activities otherwise do not involve competition with  the Company in a Conflicting
Field, either directly or  indirectly; and (iii) nothing in this Agreement shall
preclude you from holding five percent (5%) or less of the  equity interests of any
publicly-traded entity, calculated  on a fully diluted basis.  For purposes of this
Section 5  (other than Section 5(c)), the term “Company” shall be deemed
to include, where appropriate, all direct and indirect  subsidiaries of the Company. 

          (b)
In further consideration of the payments and  benefits to be provided to you pursuant to
this Agreement  (including, without limitation, pursuant to Sections 3 and  10 hereof),
you agree that, during the Term and for two  years thereafter, but subject to Sections
5(e) and 5(f)  below, you shall not, other than in connection with  performing services
for the Company or any of its Affiliates  or with the prior written consent of a
representative of the  Company specifically authorized by the Board or the  Committee to
give such consent: 

               (i)
directly or indirectly take any action, or attempt  to take any action, which is intended
to, or should  reasonably be foreseen by you to, induce a material breach  of any
material contract or agreement known to you between  the Company and any of its
licensors, licensees, clients,  customers, vendors, suppliers, agents, consultants,
employees (whether or not such employees are “at will” employees) or any other
Person with whom the Company has an  agreement (each, a “Covered Party”); 

               (ii)
directly or indirectly solicit or attempt to  solicit any Covered Party to terminate his,
her or its  relationship with the Company in breach of any material  contract or
agreement with the Company known to you; 

9 

               (iii)
directly or indirectly solicit or attempt to  solicit any individual known by you to be
an employee or  consultant of the Company to instead become an employee,  agent,
consultant, representative or advisor of any other  Person; or 

               (iv)
directly or indirectly persuade, or seek to  persuade, any customer of or supplier to the
Company to  cease to do business with the Company or to reduce the  amount of business
which such customer or supplier has done  or contemplates doing with the Company, whether
or not the  relationship between the Company and such customer or  supplier was
originally established in whole or in part  through your efforts. 

          (c)
During the Term and for two years thereafter, you  agree that (i) upon becoming employed
by a Competitor, or by  a subsidiary, division or other business unit of a  Competitor,
you will promptly provide notice to the Company  of such employment; and (ii) upon the
earlier of your (x)  negotiating with any Competitor concerning the possible  employment
of you by such Competitor, (y) receiving an offer  of employment from any Competitor, and
(z) becoming employed  by any Competitor, you will promptly provide copies of  Sections
5, 6, 7 and 8 of this Agreement to such  Competitor.  You further agree that the Company
may, during  such period, provide notice to any Competitor by which you  have become
employed, or with which you are negotiating to  become employed, of your obligations
under this Agreement,  including (without limitation) your obligations under  Sections 5,
6 and 7 hereof. 

          (d)
You understand that the provisions of this Section  5 may limit your ability to earn a
livelihood in a business  similar to the business of the Company but nevertheless  agree
and hereby acknowledge that the consideration provided  under this Agreement, including
any compensation or benefits  provided under Sections 3 and 10 hereof, is sufficient to
justify the restrictions contained in the provisions of this  Section 5. In consideration
thereof and in light of your  education, skills and abilities, you agree that you will
not  assert in any forum that such provisions prevent you from  earning a living or
otherwise are void or unenforceable or  should be held void or unenforceable. 

          (e)
Nothing in Section 5(b) above shall preclude any  Person with whom you become associated
from accepting offers  from individuals employed by the Company to be employed by  such
Person; provided that such offers were not solicited,  or otherwise encouraged, by you,
either directly or  indirectly. 

          (f)
The provisions of this Section 5 shall be null and  void in the event that, after the
Term, the Company or any  of its Affiliates materially breaches any of their material
obligations to you, under Section 10 or otherwise, which  breach is not fully cured on
fifteen days’ notice from you  to the Company requesting cure. 

     6.
Ownership of Proprietary Information. 

          (a)
You confirm and agree that all proprietary  information relating to the Company’s
business that has been  created by, discovered by, developed by, learned by, or made
known to, the Company, or assigned, licensed or otherwise  conveyed to the Company, from
the beginning of time through  the end of the Term (including, without limitation,
proprietary information relating to the Company’s business  created by, discovered
by, developed by, learned  

10 

by, reduced  to
practice by or made known to the Company, or to you,  either alone or jointly with
others, during your employment  with the Company, and proprietary information relating to
the Company’s customers, clients, suppliers, vendors,  consultants, licensors and
licensees) has been, is and shall  be the sole property of the Company, and the Company
has  been, is and shall be the sole owner of all proprietary  designs, ideas, patents,
patent applications, copyrights,  copyright applications and other rights in connection
with  such proprietary information, including but not limited to  the right to make
application for statutory protection of  any kind with respect to such proprietary
information in any  country.  All of the aforementioned information is  hereinafter
called “Proprietary Information” (and shall be  deemed Proprietary Information
regardless of whether or not  the Proprietary Information is patentable or copyrightable)
except to the extent otherwise provided in Section 6(c)  below.  By way of illustration,
but not limitation,  Proprietary Information includes, to the extent proprietary  to the
Company and except to the extent otherwise provided  in Section 6(c) below, trade
secrets, processes,  discoveries, structures, works of authorship, copyrightable  works,
trademarks, copyrights, formulas, data, data  structures, know-how, show-how,
improvements, information  relating to products (both current and under development),
services and technologies, product concepts, specifications,  techniques, information or
statistics contained in, or  relating to, promotion or marketing plans and programs,
strategies, forecasts, blueprints, sketches, records, notes,  devices, drawings, customer
lists, continuation applications  of any kind, trademark applications and information
about  the Company’s employees and/or consultants (including,  without limitation,
the compensation, job responsibilities  and job performance of such employees and/or
consultants)  and confidential business information of the Company or any  of its
clients, consultants, suppliers, customers, vendors,  licensors, licensees and other
third parties.  For purposes  of this Section 6(a), and of Section 6(b) and
6(c) below,  the term “Company” shall be deemed to include, as  appropriate,
all of the Company’s Affiliates. 

          (b)
You agree that the results of all work and tasks  performed by you for or on behalf of
the Company (“Works”)  are owned by the Company and, to the extent permitted by
law, shall be “works made for hire” as that term is defined  in the United
States Copyright Act (17 U.S.C. Section 101).  The Company shall therefore be deemed to
be the sole owner  author and owner of any and all right, title and interest in  any
Works, including, without limitation, all intellectual  property rights therein.  You
hereby assign to the Company  all right, title and interest you may have or acquire in
any  Works. 

          (c)
Notwithstanding the foregoing, Proprietary  Information shall not include: (i)
information in the public  domain not as a result of any breach of this Agreement or of
any duty owed by you to the Company or any other Person;  (ii) information lawfully in
your possession prior to the  commencement of your employment with the Company and not
disclosed to you by the Company; or (iii) information  disclosed to you without
restriction by a third party who  had the right to disclose such information to you. 

          (d)
It is understood that no patent, copyright,  trademark, or other proprietary right or
license is granted  to you under this Agreement.  Any disclosure of Proprietary
Information, and any materials which may accompany any such  disclosure, in the course of
your employment under this  Agreement shall not result in the grant to you of any
proprietary rights, express or implied, of any kind as  against the Company. 

11 

          (e)
During the Term and thereafter, you agree that you  will, upon reasonable request by the
Company, promptly  disclose to the Company, or any Person reasonably designated  by the
Company, all Proprietary Information that you know or  possess and that has been
developed, created, made,  conceived, reduced to practice or learned by the Company,  any
Affiliate of the Company, or you, either alone or  jointly with others, during the Term
and is not otherwise  known to the Company’s officers and directors. 

          (f)
Any assignment of copyright under this Agreement  includes all rights of paternity,
integrity, disclosure and  withdrawal and other rights relating thereto that may be
known as or referred to as “moral rights” (collectively,  “Moral Rights”).
To the extent such Moral Rights cannot be  assigned under applicable law and to the
extent the  following is allowed by the laws in the various countries  where such Moral
Rights exist, you hereby waive such Moral  Rights and consent to any action of the
Company that would  violate such Moral Rights in the absence of such consent.  You agree
to confirm any such waivers and consents from time  to time as requested by the Company. 

          (g)
You further agree to assist the Company, upon  reasonable request by the Company and both
during and after  the Term (but at the Company’s sole expense), to obtain,  confirm
and from time to time enforce patents, copyrights or  other rights relating thereto on
Works in any and all  countries, and to that end you will, upon reasonable request  by
the Company, execute any documents reasonably necessary:  (i) to apply for, obtain and
vest in the name of the Company  alone (unless the Company otherwise directs) letters
patent,  copyrights or other analogous protection with respect to  Works in any country
throughout the world and when so  obtained or vested to renew and restore the same on
behalf  of the Company; and (ii) to defend any opposition  proceedings in respect of such
applications and any  opposition proceedings or petitions or applications for  revocation
of such letters patent, copyright or other  analogous protection. 

          (h)
Your obligation to assist the Company, upon  reasonable request by the Company, in
obtaining and  enforcing patents and copyrights for Works in any and all  countries, and
in resisting disclosure of Proprietary  Information as provided in Section 7(d)
below, and in  otherwise carrying out your obligations under Sections 6 and  7,
shall continue beyond the Term to the extent provided  herein, but the Company agrees to
compensate you, on an  hourly basis based on an eight hour day at a daily rate  $1,500,
for time actually spent by you after the Term at the  Company’s request on such
matters. 

     7.
Use and Disclosure of Proprietary Information. 

          (a)
You agree at all times, including after the Term,  (x) to keep in strict trust and
confidence, and not to  disclose or make accessible to any other Person other than  with
the prior written consent of a representative of the  Company specifically authorized by
the Board or the  Committee to give such consent, Proprietary Information of  the Company
and its Affiliates, and (y) not to use any such  Proprietary Information for yourself or
others; provided  that the provisions of this Section 7(a) shall not prohibit  or
restrict use or disclosure in connection with the proper  discharge of your services for
the Company or any of its  Affiliates or as otherwise provided in this Agreement. 

12 

          (b)
You further agree not to disclose or publish at any  time, during or after the Term, and
in violation of any  obligation of confidence owed by you, information relating  to any
of your former employers. 

          (c)
Upon lawful written notice by the Company to you  either during or after the Term, you
shall promptly deliver  to the Company, or, if requested by the Company, promptly
destroy, all written Proprietary Information and any other  material containing any
Proprietary Information (whether  prepared by the Company, you or a third party) that is
in  physical (including, without limitation, electronic) form  and that is in your
possession, and will not retain any  copies, extracts, summaries or other reproductions
in whole  or in part of such written Proprietary Information or other  material; provided
that you shall in all instances be  permitted to retain, and use appropriately: (x) your
personal correspondence files, rolodex, and the like and (y)  documents relating to your
benefits, entitlements,  compensation, tax obligations, and the like. 

          (d)
If during the Term or thereafter you are required  by law, or by order, subpoena or
comparable process from an  arbitrator, court, agency or other Person, to disclose all
or any part of any Proprietary Information, other than as  contemplated elsewhere in
Sections 6 and 7, you will provide  the Company with prompt written notice of such
requirement,  and of the terms and circumstances surrounding such  requirement, so that
the Company, or, as applicable, one or  more of its Affiliates, may seek an appropriate
protective  order or waive compliance with the provisions of this  Agreement.  In such
case, the Parties will consult with each  other on the advisability of pursuing any such
order or  other legal action or available steps to resist or narrow  such requirement.
If, failing the entry of a protective  order or the receipt of a waiver hereunder, you
are, in the  opinion of your counsel, legally compelled to disclose  Proprietary
Information, you may disclose only that portion  of such information which counsel
advises you that you are  legally compelled to disclose.  In any event, you will
cooperate reasonably with the Company in obtaining, and will  not oppose action by the
Company (or, as applicable, one or  more of its Affiliates) to obtain, an appropriate
protective  order or other reliable assurance that confidential  treatment will be
accorded the disclosure of any Proprietary  Information.  All expenses reasonably
incurred by you in  complying with Sections 6 and 7 (including, without  limitation,
fees and other charges of counsel) will be  promptly reimbursed by the Company. 

     8.
            Enforcement.  You agree that the remedy at law for  any breach or threatened breach by
you of any covenant  contained in Sections 5, 6 or 7 of this Agreement would be
inadequate and cause irreparable damage to the Company.  In  the event that you breach or
threaten to breach any  provisions of Sections 5, 6 or 7, in addition to any other
rights which the Company may have at law or in equity, the  Company shall be entitled,
without the posting of a bond or  other security, to seek injunctive relief from any
court of  competent jurisdiction to enforce the restrictions contained  in such Sections.
In the event that an actual proceeding is  brought in equity to enforce any of the
provisions of  Sections 5, 6 or 7, you shall not assert as a defense that  there is an
adequate remedy at law, nor shall the Company be  prevented from seeking any other
remedies that may be  available to it (including, without limitation, monetary  damages)
through arbitration in accordance with Section 12  below.  The prevailing party in any
contested request for  injunctive relief under this Section 8 shall be entitled to
prompt  

13 

reimbursement
for such party’s reasonable attorneys’ fees, and for other costs and expenses
reasonably incurred  by such party, in connection with such request. 

     9.
            Termination.  Your employment hereunder, and the  Term, shall terminate upon the first to
occur of the  following events: 

          (a)
Death. You die. 

          (b)
            Disability. You have been unable, for 120 or more  days out of 180 consecutive days, to
perform your duties  under this Agreement, as a result of physical or mental  illness,
injury or incapacity, and the Company shall have  communicated to you, by written notice,
the fact of your  termination, which termination shall be effective on the  30th day
after receipt of such notice by you, unless you  return to full-time performance of your
duties hereunder  prior to such 30th day. 

          (c)  For Cause.  Your employment hereunder may be  terminated by the Company for Cause in
accordance with this  Section 9(c). 

               (i)
No termination of your employment hereunder for  Cause shall be effective as a
termination for Cause unless  the provisions of this Section 9(c)(i) shall first have
been  complied with.  You shall be given written notice by the  Board of its intention to
terminate you for Cause, such  notice (x) to state in detail the particular circumstances
that constitute the grounds on which the proposed  termination for Cause is based and (y)
to be given no later  than 90 days after the Board, as a whole, is first made  aware of
such circumstances.  You shall have five business  days after receiving such notice in
which to request a  hearing before the Board, which hearing (if timely  requested) shall
be held within ten business days of your  receiving such notice.  If, within 20 business
days  following such hearing (if timely requested), or within ten  business days
following your receipt of the original notice  (if no hearing is timely requested), the
Board gives written  notice to you confirming that, in the judgment of at least  two
thirds of the members of the Board (not including you,  if you are then a member of the
Board), Cause for  terminating your employment on the basis set forth in the  original
notice exists, your employment hereunder shall  thereupon be terminated for Cause,
subject to de novo  review, at your election, of the question whether Cause  existed
through arbitration in accordance with Section 12  below.  Notwithstanding anything
herein to the contrary, the  Board may cause you to be on administrative leave (with full
pay and benefits) during a period, not longer than 20  business days, that begins on the
date that the Company  gives the original notice provided for in this Section  9(c)(i)
and ends on the earlier of (x) the date that your  employment hereunder is terminated for
Cause and (y) the  date that the Board determines that your employment  hereunder will
not be terminated for Cause. 

          (ii)
For purposes of this Agreement, the term “Cause” shall mean the occurrence of
any of the following: (A) any  willful and material breach by you of any of the
provisions  of Sections 5, 6, or 7 above, which breach causes or is  likely to cause
material harm to the Company; (B) any  willful and material breach by you of Section 1(b)
or 1(c)  above, which breach is not cured by you on 30 days’ written  notice thereof
from the Company requesting cure; provided,  however, that your right to such 30-day cure
period shall be  conditioned upon your  

14 

good-faith
attempt to cure such  breach; (C) any act or omission by you that constitutes
misconduct, is intended to harm the Company, and causes or  is likely to cause material
harm to the Company; (D) any  conduct by you that constitutes willful gross misconduct,
or  willful gross neglect, and that causes or is likely to cause  material harm to the
Company; (E) the perpetration by you of  an intentional and knowing fraud against, or
adversely  affecting, the Company or any of its Affiliates, which fraud  causes or is
likely to cause material harm to the Company;  or (F) you are convicted of, or plead
guilty or nolo  contendere to, any felony. 

          (d)
            Without Cause.  The Company may terminate your  employment hereunder at any time, for any
reason or no  reason, by giving you ten days’ prior written notice of the
termination.  No such termination of your employment  hereunder shall be deemed a breach
of this Agreement. 

          (e)
            For Good Reason.  You may terminate your employment  hereunder for  “Good Reason” on
ten days’ written notice to  the Company following the occurrence of any of the
following  without your prior written consent: (i) you are assigned  duties that are
inconsistent in any material respect with  Section 1(b) above, or your titles, positions,
authorities,  duties or responsibilities are materially diminished, in  each case without
full cure on 30 days’ written notice from  you to the Company requesting cure;
provided that the  Company becoming a subsidiary of another entity, or  otherwise ceasing
to be a publicly-traded company, shall not  in and of itself constitute circumstances
described in this  clause (i) unless an assignment or diminishment described in  this
clause (i) occurs in connection therewith; (ii) any  failure by the Company to timely
comply with its obligations  to you under Section 3 above, or with any other material
obligation to you, that is not fully cured on 30 days’ written notice from you to
the Company requesting cure;  (iii) your failure to be re-elected to the Board or as
Chairman of the Board, unless, at the time you are not  re-elected, the Company has the
right to terminate your  employment hereunder for Cause under Section 9(c) above and
does so within 45 days of your failure to be re-elected;  (iv) any change in your
reporting structure so that you are  required to report, in your capacity as Chief
Executive  Officer of the Company, to any Person other than the Board  that is not fully
cured on ten days’ written notice from you  to the Company requesting cure; (v) any
relocation of the  Company’s headquarters, or of your principal place of
employment, to a location that is more than 75 miles from  Berkeley Heights, New Jersey;
or (vi) any failure by the  Company to obtain the assumption in writing of its
obligations under this Agreement by any successor to all or  substantially all of its
business or assets within 15 days  after any reconstruction, amalgamation, combination,
merger,  consolidation, sale, liquidation, dissolution or similar  transaction; provided,
however, that if your failure to be  elected as Chairman of the Board is solely on
account of the  Board determining in good faith, pursuant to written advice  from
nationally-recognized outside counsel, that the same  person should not serve as both
Chairman of the Board and  Chief Executive Officer of the Company, then such failure
shall not constitute Good Reason.  In addition, any  termination by you, on 30 days’ written
notice from you to  the Company, of your employment hereunder during any 30-day  period
that commences 365 days after the occurrence of any  Change in Control shall be treated
as a termination by you  for “Good Reason”.  For purposes of this Agreement,
“Change  in Control” shall mean “Change in Control” as defined in the
1998 Plan. 

15 

          (f)
            Without Good Reason.  You may terminate your  employment hereunder at any time, for any
reason or no  reason, by giving 30 days’ prior written notice of  termination to the
Company.  No such termination of your  employment hereunder shall be deemed a breach of
this  Agreement. 

          (g)
            Expiration of Term.  Your employment hereunder  shall terminate upon expiration of the
Term pursuant to  notice of non-extension given by either Party in accordance  with
Section 2. 

     10.
            Benefits Upon Termination of Your Employment  Hereunder.  In the event that your
employment hereunder is  terminated, you shall be entitled to the following  compensation
and benefits: 

          (a)
            Any Termination.  On any termination of your  employment hereunder, you shall be entitled
to the following  benefits: 

               (i)
prompt payment of any accrued but unpaid Base  Salary through the date that your
employment hereunder  terminates (the “Termination Date”); 

               (ii)
prompt payment of any accrued but unpaid expenses  required to be reimbursed pursuant to
Section 3 above; 

               (iii)
unless the termination is (x) by the Company for  Cause in accordance with Section 9(c)
above or (y) by you  voluntarily without Good Reason and not pursuant to notice  of
non-extension in accordance with Section 2 above, a  prompt lump-sum payment in respect
of accrued but unused  vacation days at your per-business-day Base Salary rate in  effect
as of the Termination Date; 

               (iv)
prompt payment of any accrued but unpaid Bonus  amount; 

               (v)
unless the termination is (x) by the Company for  Cause in accordance with Section 9(c)
above or (y) by you  voluntarily without Good Reason and not pursuant to notice  of
non-extension in accordance with Section 2 above, a  lump-sum payment equal to the
product obtained by  multiplying (A) the Bonus to which you would have been  entitled for
the calendar year of termination if you had  remained employed hereunder throughout such
calendar year  times (B) a fraction whose numerator equals the number of  days you were
employed hereunder during such calendar year  and whose denominator is 365, such payment
to be due to you  at the time your Bonus for such calendar year would have  been due if
you had remained employed hereunder; 

               (vi)
other or additional benefits in accordance with  applicable plans, programs, agreements
and arrangements of  the Company and its Affiliates (including, without  limitation,
Sections 3, 6(h) and 7(d) above and Section 12  below, and applicable stock option
agreements, retirement  plans, disability/life insurance programs, etc.); and 

16 

               (vii)
payment, promptly when due, of all amounts referred  to above, such payments to be made
by wire transfer of  same-day funds to the extent reasonably requested by you. 

          (b)
            Termination without Cause or for Good Reason.  In  the event that your employment
hereunder is terminated  (x) by the Company (other than for death, for disability in
accordance with Section 9(b), for Cause in accordance with  Section 9(c), or
pursuant to a notice of non-extension in  accordance with Section 2), or (y) by
you for Good Reason in  accordance with Section 9(e), you shall receive the
following benefits provided, except as set forth in Section  10(b)(i) and 10(b)(v) below,
that you execute, and do not  revoke, a mutual release that is in substantially the form
attached hereto as Exhibit B: 

               (i)
the benefits described in Section 10(a) (you will  receive these benefits regardless
of whether you execute a  release); 

               (ii)
subject to your not having materially breached the  provisions of Section 5, which breach
has not been fully  cured (if capable of cure) on fifteen days’ notice to you  from
the Company requesting cure, continued payment of your  Base Salary through the first
anniversary of the Termination  Date; provided that, in the event that such termination
of  your employment is either (x) by the Company in anticipation  of a Change in Control
or (y) by either Party upon the  occurrence of, or within 13 months following, a Change
in  Control, then you shall instead receive a prompt lump-sum  payment equal to two times
your annualized Base Salary; 

               (iii)
subject to your not having materially breached the  provisions of Section 5, which breach
has not been fully  cured (if capable of cure) on fifteen days’ notice to you  from
the Company requesting cure, in the event that such  termination of your employment is
either (x) by the Company  in anticipation of a Change in Control or (y) by either  Party
upon the occurrence of, or within 13 months following,  a Change in Control, then you
shall receive a prompt  lump-sum payment equal to two times your target Bonus for  the
calendar year of termination (i.e., forty percent of  your annualized Base Salary); 

               (iv)
each of your outstanding stock options shall, to  the extent vesting or exercisability
depends solely on your  continued employment, become fully vested, and fully
exercisable, as of the Termination Date (provided that, for  avoidance of doubt, the
Second Tranche for 500,000 shares  granted pursuant to Section 2(c) of Exhibit A attached
hereto shall, for purposes of this Section 10, be deemed not  to vest or become
exercisable based solely on your continued  employment); and 

               (v)
each of your outstanding stock options shall, to  the extent that it is or becomes
exercisable as of the  Termination Date, remain exercisable in accordance with its  terms
(you will receive these benefits regardless of whether  you execute a release). 

          (c)
            Expiration of the Term.  In the event that your  employment hereunder terminates by
expiration of the Term  pursuant to notice of non-extension in accordance with  Section
2, you shall be entitled to the following benefits  provided, except as set forth in
Section 10(c)(i) and 10  (c)(iv) below, that you execute, and do not revoke, a mutual
release that is in substanially the form attached hereto as  Exhibit B. 

17 

               (i)
the benefits described in Section 10(a) (you will  receive these benefits regardless
of whether you execute a  release); 

               (ii)
if the Term expires pursuant to notice of  non-extension from you, each of your
outstanding stock  options whose vesting or exercisability depends solely on  your
continued employment shall vest, and become fully  exercisable, as of the Termination
Date to the extent that  such stock option was then scheduled to become vested or
exercisable within 90 days following the Termination Date  had your employment
hereunder continued; 

               (iii)
if the Term expires pursuant to notice of  non-extension from the Company, each of your
outstanding  stock options whose vesting or exercisability depends solely  on your
continued employment shall become fully vested, and  fully exercisable, as of the
Termination Date; and 

               (iv)
each of your outstanding stock options shall, to  the extent that it is or becomes
exercisable as of the  Termination Date, remain exercisable in accordance with its  terms
(you will receive thes benefits regardless of whether  you execute a release). 

          (d)
            No Mitigation; No Offset.  In the event of any  termination of your employment hereunder,
you shall have no  obligation to seek other employment or otherwise mitigate  the
obligations of the Company under this Agreement, and  there shall be no offset against
amounts or benefits due to  you under this Agreement or otherwise on account of (x) any
Claim that the Company or any of its Affiliates may have  against you or (y) any
remuneration or other benefit earned  or received by you after such termination.  Any
amounts due  under this Section 10 are considered to be reasonable by the  Company and
are not in the nature of a penalty. 

          (e)
            No Other Benefits or Compensation.  Except as may  be provided under this Agreement or
under the terms of any  incentive compensation, employee benefit or fringe benefit  plan
applicable to you as of the Termination Date, you shall  have no right to receive any
other compensation, or to  participate in any other plan, arrangement or benefit, with
respect to any future period after such date. 

     11.
            Notices.  Any notice, consent, demand, request, or  other communication given to a Person
in connection with  this Agreement shall be in writing and shall be deemed to  have been
given to such Person (x) when delivered personally  to such Person or (y) provided that a
written acknowledgment  of receipt is obtained, five days after being sent by  prepaid
certified or registered mail, or two days after  being sent by a nationally recognized
overnight courier, to  the address (if any) specified below for such Person (or to  such
other address as such Person shall have specified by  ten days’ advance notice given
in accordance with this  Section 11) or (z), in the case of the Company only, on the
first business day after it is sent by facsimile to the  facsimile number set forth below
(or to such other facsimile  number as shall have specified by ten days’ advance
notice  given in accordance with this Section 11), with a  confirmatory copy sent by
certified or registered mail or by  overnight courier in accordance with this Section 11. 

18 

	 	If to the Company:	Genta Incorporated 

      Two Connell Drive 

      Berkeley Heights, NJ
      07922 

      Attn: General Counsel and
      Board of Directors 

    Fax #: 908-286-1701 
	 	 	 
	 	With a copy to:	Fox Rothschild 

      P.O. Box 5231 

      Princeton, NJ 08543-5231 

      Attn: Sally Howe, Esq. 

    Fax: 609.896.1469 
	 	 	 
	 	If to you: 	The address of your
      principal residence as it
      appears in the Company’s
      records, with a copy to
      you (during the Term) at
      your office in Berkeley
    Heights, New Jersey 
	 	 	 
	 	With a copy to: 	Morrison Cohen LLP 

      909 Third Avenue 

      New York, NY 10022 

      Attn: Robert M. Sedgwick,
      Esq. 

    Fax #: 212-735-8708 
	 	 	 
	 	If to any of your
    beneficiaries: 

    	The address most recently
      specified by you or by
    such beneficiary. 

     12.  Resolution of Disputes.  Any Claim arising out of  or relating to this Agreement, any
other agreement between  you and the Company or any of its Affiliates, your  employment
with the Company, or any termination thereof (a  “Covered Claim”) shall (except
to the extent otherwise  provided in Section 8 with respect to certain requests for
injunctive relief) be resolved by binding confidential  arbitration, to be held in the
Borough of Manhattan in New  York City, in accordance with the Commercial Arbitration
Rules (and not the National Rules for Resolution of  Employment Disputes) of the American
Arbitration Association  and this Section 12.  Judgment upon the award rendered by
the arbitrator(s) may be entered in any court having  jurisdiction thereof.  To the
extent that it is determined  through arbitration that you substantially prevailed in
respect of a Covered Claim (and the Parties agree to request  the arbitrator(s) appointed
pursuant to this Section 12 to  determine whether or not you did so), the Company shall
reimburse all reasonable costs and expenses (including,  without limitation, attorneys’ fees
and other charges of  counsel) incurred by you or your beneficiaries in resolving  such
Covered Claim.  Pending the resolution of any Covered  Claim, you (and your
beneficiaries) shall continue to  receive all payments and benefits that are then due
(under  this Agreement or otherwise) and that are not the  

19 

subject of
reasonable, good-faith dispute, unless the arbitrator(s)  appointed pursuant to this
Section 12 determines otherwise. 

     13.
            Severability of Provisions.  If any provision of  this Agreement shall be declared by any
court or arbitrator  of competent jurisdiction to be invalid, illegal or  incapable of
being enforced in whole or in part, the  remaining conditions and provisions or portions
thereof  shall nevertheless remain in full force and effect and  enforceable to the
extent they are valid, legal and  enforceable.  If any provision of this Agreement, or
any  part thereof, is held to be invalid or unenforceable because  of the scope or
duration of or the area covered by such  provision, the Parties agree that the court or
arbitrator  making such determination shall reduce the scope, duration  and/or area of
such provision (and shall substitute  appropriate provisions for any such invalid or
unenforceable  provisions) in order to make such provision enforceable to  the fullest
extent permitted by law and/or shall delete  specific words and phrases, and such
modified provision  shall then be enforceable and shall be enforced.  The  Parties
recognize that if, in any Proceeding, a court or  arbitrator shall refuse to enforce any
of the separate  covenants contained in this Agreement, then that invalid or
unenforceable covenant contained in this Agreement shall be  deemed eliminated from these
provisions to the extent  necessary to permit the remaining separate covenants to be
enforced.  In the event that any court or arbitrator  determines that the time period or
the area, or both, are  unreasonable and that any of the covenants is to that extent
invalid or unenforceable, the Parties agree that such  covenants shall remain in full
force and effect, first, for  the greatest time period, and second, in the greatest
geographical area that would not render them unenforceable. 

     14.
Entire Agreement; Modification; Inconsistencies. 

          (a)
This Agreement contains the entire understanding  and agreement between the Parties
concerning the specific  subject matter hereof and supersedes in its entirety, as of  the
Effective Date, any prior employment agreement between  the Parties;  provided, however,
that nothing herein shall  limit or reduce any right or benefit that shall have accrued
to you as of the Effective Date, under any prior employment  agreement or otherwise, on
account of events occurring prior  to the Effective Date, or any right under the second
sentence of Section 3(c) of the October 28, 1999 employment  agreement between the
Parties in respect of stock options  granted prior to the Effective Date pursuant to such
Section  3(c). 

          (b)
No provision in this Agreement may be amended  unless such amendment is set forth in a
writing that  expressly refers to the provision of this Agreement that is  being amended
and that is signed by you and by an authorized  representative of the Company.  No waiver
by any Person of  any breach of any condition or provision contained in this  Agreement
shall be deemed a waiver of any similar or  dissimilar condition or provision at the same
or any prior  or subsequent time.  To be effective, any waiver must be set  forth in a
writing signed by the waiving Person and must  specifically refer to the condition(s) or
provision(s) of  this Agreement being waived. 

20 

          (c)
In the event of any inconsistency between any  provision of this Agreement and any
provision of any  employee handbook, personnel manual, program, policy,  arrangement,
agreement, plan, or corporate governance  document of the Company or any of its
Affiliates, the  provisions of this Agreement shall control unless you  otherwise agree
in a writing that expressly refers to the  provision of this Agreement whose control you
are waiving. 

     15.
Assignability; Binding Nature. 

          (a)
This Agreement shall be binding upon and inure to  the benefit of the Parties and their
respective successors,  heirs (in your case) and assigns. 

          (b)
No rights or obligations of the Company under this  Agreement may be assigned or
transferred by the Company  except that such rights and obligations may be assigned or
transferred pursuant to a merger, consolidation or other  combination in which the
Company is not the continuing  entity, or a sale or liquidation of all or substantially
all  of the business and assets of the Company; provided that the  assignee or transferee
is the successor to all or  substantially all of the business and assets of the Company
and such assignee or transferee expressly assumes the  liabilities, obligations and
duties of the Company as set  forth in this Agreement.  In the event of any merger,
consolidation, other combination, sale of business and  assets, or liquidation as
described in the preceding  sentence, the Company shall use its best reasonable efforts
to cause such assignee or transferee to promptly and  expressly assume the liabilities,
obligations and duties of  the Company hereunder. 

          (c)
None of your rights or obligations under this  Agreement may be assigned or transferred
by you other than  your rights to compensation and benefits, which may be  transferred
only by will or by operation of law, except that  you shall be entitled, to the extent
permitted under  applicable law, to select and change a beneficiary or  beneficiaries to
receive any compensation or benefit  hereunder following your death by giving written
notice  thereof to the Company. 

     16.
Miscellaneous. 

          (a)
In the event of your death or a judicial  determination of your incompetence, references
in this  Agreement to you shall be deemed, where appropriate, to  refer to your
beneficiary, estate or other legal  representative. 

          (b)
This Agreement shall be governed, construed and  enforced in accordance with its express
terms, and otherwise  in accordance with the laws of the State of New York without
regard to principles of conflict of laws. 

          (c)
Except as otherwise set forth in this Agreement,  the respective rights and obligations
of the Parties  hereunder shall survive any termination of your employment  hereunder. 

          (d)
The headings of Sections and subsections of this  Agreement are inserted for convenience
only and shall not  affect any interpretation of this Agreement. 

21 

[Remainder
of page intentionally left blank; signature page  follows]

22 

          If
this letter agreement meets with your  approval and you desire to accept this offer of
employment  on the terms and conditions set forth herein, please execute  the enclosed
copy of this letter and return it to me as soon  as possible.  Signatures delivered by
facsimile shall be  effective for all purposes. 

	 	 Sincerely,
	 	 	 
	 	 GENTA INCORPORATED
	 	 	 
	 	By: 	/s/ Daniel Von Hoff,
      M.D.
	 	 	

	 	Name: 	Daniel Von Hoff, M.D.
	 	 Title:	 Chairman
of the
Compensation
        

      Committee
of
the
Board
	 	 Date:	March
31,
2006

	AGREED AND ACCEPTED:	 
	 	 
	/s/
      Raymond P. Warrell, Jr., M.D.	 
	
	 
	Dr. Raymond P. Warrell,
      Jr., M.D.	 
	Date: March 31, 2006	 

23 

EXHIBIT A

FORM OF
STOCK OPTION AGREEMENT

     1.
            Grant of Option.  Genta Incorporated, a Delaware  corporation (together with its
successors and assigns, the  “Company”), hereby grants to Dr. Raymond P.
Warrell, Jr. (the  “Optionee”), effective as of March  31, 2006 (the “Grant
Date”), an option (as more fully defined below the “option”)  under the
Company’s 1998 Stock Incentive Plan, as amended  through the Grant Date (the “Plan”),
to purchase an  aggregate of 1,000,000 shares of the Company’s Common Stock  (each
such share, a “Share”) at an exercise price of $2.16  per Share (the “Exercise
Price”) equal to the Fair Market  Value on the Grant Date, exercisable as set forth
in, and  subject to the terms and conditions of, the Plan, this Stock  Option Agreement
(this “Stock Option Agreement”) and the  letter agreement dated as of January
1, 2006, between the  Company and the Optionee relating to the Optionee’s
employment with the Company (the “Employment Agreement”).  All capitalized
terms not defined in this Stock Option  Agreement shall have the meanings set forth in
the  Employment Agreement.  “Term of Employment” shall mean  “Term” as
defined in the Employment Agreement, and the terms  “Fair Market Value” and
“Change in Control” shall mean “Fair  Market Value” and “Change
in Control” as defined in the Plan. 

     2.
Exercisability of Option. 

          (a)
The option granted hereby to the Optionee shall be  divided into two tranches, each
consisting of 500,000 Shares  (sometimes referred herein individually as a “Tranche” and
collectively, as the “Tranches”) that are distinguished as  to the terms over
which the Shares to which they  respectively relate become exercisable as more fully
described in this Section 2. 

          (b)
The first Tranche (the “Standard Tranche”) relates  to an aggregate of 500,000
Shares that, subject to the  provisions of Sections 2(d) through 2(i), inclusive,  will
become exercisable (“vest”) over a period of three (3) years  from the Grant
Date, by means of (i) an initial amount of  41,664 Shares to be exercisable and vest on
the Grant Date,  (ii) an additional amount of 444,416 Shares to become  exercisable and
vest in thirty-two (32) equal monthly  increments of 13,888 Shares each, commencing on
April  1,  2006 and continuing on the first day of each of the next  successive
thirty-one (31) calendar months, and (ii) a final  amount of 13,920 Shares to become
exercisable and vest on  December 1, 2008. 

          (c)
The second Tranche (the “Genasense Tranche”)  relates to an aggregate of
500,000 Shares that, subject to  the provisions of Sections 2(d) through 2(i), inclusive,
will become exercisable and vest in the event that the  Company achieves any one or more
of the specified milestones  listed in items (i) through (iii) immediately below
(individually, a “Milestone” and collectively,  “Milestones”),
respecting the Genasense product or its  substantial equivalent (collectively, the “Genasense
Product”) that is currently being developed by the Company.  Each of the Milestones
listed in items (i) through (iii)  immediately below is independent of the others as to
vesting. 

24 

               (i)
A total of 150,000 of the 500,000 Shares contained  in the Genasense Tranche will become
exercisable on the date  that the Genasense Product receives approval for any first
indication in the United States from the Food and Drug  Administration. 

               (ii)
A total of 150,000 of the 500,000 Shares contained  in the Genasense Tranche will become
exercisable on the date  that the Genasense Product receives approval for any first
indication in Europe from the European Medicines Agency. 

               (iii)
A total of 200,000 of the 500,000 Shares contained  in the Genasense Tranche will become
exercisable on the  first day of the month immediately following the first  twelve
consecutive month period during which the Company  realizes net revenues on sales of the
Genasense Product of  $100,000,000 or more. 

          (d)
If any of the following events (each, a “Trigger  Event”) occurs (x) on or
before December 31, 2008 and (y)  either during the Term of Employment or, in the event
that  the Optionee’s employment is terminated by the Company  without Cause in
anticipation of the occurrence of a Trigger  Event, within three months after such
termination, then this  option, comprised of the Shares in both the Standard Tranche  and
the Genasense Tranche, shall become fully vested, and  fully exercisable, upon the
occurrence of a Trigger Event,  provided that the Fair Market Value of a Share as of the
date of the occurrence of such Trigger Event equals or  exceeds $5.00: 

               (i)
a sale or other disposition of the product G3139 or  its substantial equivalent; or 

               (ii)
a Change in Control. 

          (e)
In the event that the Optionee’s employment with  the Company is terminated other
than in a termination (x) by  the Company for Cause in accordance with Section 9(c) of
the  Employment Agreement or (y) by the Optionee voluntarily,  other than for Good
Reason, then this option shall remain  exercisable, subject to Section 2(i) below, to the
extent  that it either is exercisable as of the date that the  Optionee’s employment
terminates or becomes exercisable  within three months thereafter upon the occurrence of
a  Trigger Event pursuant to Section 2(d) above, through the  second anniversary of the
date that the Optionee’s  employment terminates, at which time it shall expire to
the  extent that it has not yet been exercised. 

          (f)
In the event that the Optionee’s employment with  the Company is terminated by the
Optionee voluntarily, other  than for Good Reason, then, subject to Section 2(i) below,
this option shall remain exercisable, to the extent that it  is exercisable as of the
date that the Optionee’s employment  terminates, through the first anniversary of
the date that  the Optionee’s employment terminates, at which time it shall  expire
to the extent that it has not yet been exercised. 

          (g)
In the event that the Optionee dies on or before  the date that this option expires,
then, subject to Section  2(i) below,  this option shall remain exercisable, to the
extent  

25 

that it is
exercisable as of the date of the  Optionee’s death through the later of the first
anniversary  of the date of the Optionee’s death and, in the event that  the Optionee’s
employment with the Company previously  terminated in a termination governed by Section
2(e) above,  the expiration date that applies under Section 2(e) above,  at which time it
shall expire to the extent that it has not  yet been exercised. 

          (h)
In the event that the Optionee’s employment with  the Company is terminated for
Cause in accordance with  Section 9(c) of the Employment Agreement, then this option
shall expire as of the Termination Date. 

          (i)
Anything elsewhere to the contrary notwithstanding,  this option shall, to the extent
that it has not yet then  expired or been exercised, expire at 11:59 p.m. on the tenth
anniversary of the Grant Date. 

     3.
Exercise of Option. 

          (a)
            Method of Exercise.  Subject to the conditions set  forth in this Stock Option Agreement,
this option may be  exercised from time to time by delivery of written notice of
exercise to the Company from the Optionee.  Such notice  shall specify the total number
of Shares to be purchased and  shall be accompanied by payment in full (or an arrangement
for payment in full) in accordance with Section 3(b) below.  Such exercise shall be
effective upon delivery to the  Company of such written notice together with the required
payment (or arrangement for payment).  This option may be  exercised for less than the
full number of Shares for which  it is then exercisable, provided that no such exercise
may  be for any fractional Share. 

          (b)
            Method of Payment.  Payment of the purchase price  for Shares purchased upon an exercise
of this option may be  made: (i) by delivery to the Company of cash, a wire  transfer of
available funds, or a check payable to the order  of the Company and backed by sufficient
funds, in each case  in an amount equal to the purchase price of such Shares;  (ii) by
delivery to the Company of Shares then owned by the  Optionee having an aggregate Fair
Market Value as of the  date of delivery equal to the purchase price of such Shares,
      provided that payment in this fashion does not result in an  accounting charge to the
Company’s earnings that is greater  than the accounting charge (if any) that would
have applied  if the payment had been made in cash; (iii) subject to the  restrictions
contained in Section 3(g) of the Employment  Agreement and to the extent then allowed by
applicable law,  through reasonable cashless exercise procedures that are  from time to
time established or approved by the Company and  that afford the Optionee the opportunity
to sell immediately  some or all of the Shares underlying the exercised portion  of this
option in order to generate sufficient cash to pay  the option purchase price, providedthat the Company shall  not unreasonably delay establishing, or approving, such
procedures upon reasonable request by the Optionee; (iv) by  authorizing the Company to
withhold Shares that would  otherwise be delivered on such exercise having a Fair Market
Value on the date of exercise equal to the amount of the  purchase price, provided that
payment in this fashion is  allowable only if the Company applies FAS 123(R), or a
successor thereto, to this option and, as a result, the  accounting consequences of
exercising this option in this  manner are no different than if the Exercise Price was
payable solely in cash; (v) to the extent then allowed by  applicable law, by delivering
to the Company a full recourse  three-year promissory note  

26 

which shall (A)
bear interest,  payable at maturity, at the applicable federal rate (as  defined in and
under Section 1274(d) of the Internal Revenue  Code of 1986, as amended, and the rules
and regulations  promulgated thereunder), and (B) be secured by a pledge of  the Shares
delivered on such exercise, subject to the  Optionee’s right to sell such Shares
within the limitations  described in Section 3(g) of the Employment Agreement and  remit
the after-tax proceeds of such sale to the Company in  repayment of such note; or (vi) by
any combination of (i),  (ii), (iii), (iv) or (v). 

          (c)
            Delivery of Shares Tendered in Payment of Purchase  Price.  Payment by delivery of Shares
may be effected by  delivering one or more stock certificates or by otherwise  delivering
Shares to the Company’s reasonable satisfaction  (including, without limitation,
through an “attestation” procedure that is reasonably acceptable to the
Company), in  each case accompanied by such endorsements, stock powers,  signature
guarantees or other documents or assurances as may  reasonably be required by the
Company.  If a certificate or  certificates or other documentation representing Shares in
excess of the amount required are delivered, a certificate  (or other satisfactory
evidence of ownership) representing  the excess number of Shares shall promptly be
returned by  the Company. 

          (d)
            Delivery of Option Shares.  The Company shall, upon  payment in accordance with Section
3(b) above of the  aggregate purchase price for the number of Shares purchased,  make
prompt delivery of such Shares to the Optionee and pay  all original issue and transfer
taxes and all other fees and  expenses incident to such delivery.  All Shares delivered
upon any exercise of this option shall, when delivered: (i)  be duly authorized, validly
issued, fully paid and  nonassessable; (ii) be registered, or otherwise qualified,  for
sale, and for resale, under state and Federal securities  laws to the extent that other
Shares of the same class are  then so registered or qualified; provided, however, that in
no event shall the Company be required to prepare and file a  Form S-3 reoffer
prospectus; and (iii) be listed, or  otherwise qualified, for trading on any securities
exchange  or securities market on which Shares of the same class are  then listed or
qualified.  To the extent that Shares are not  promptly delivered to the Optionee when
due, the Company  shall promptly make the Optionee whole for any resulting  expense or
loss of benefit.  The Company shall deliver cash  in lieu of any fractional Share.
Section 2.10 of the Plan  shall not apply to this option. 

          (e)
            Tax Withholding.  The Company’s obligation to  deliver Shares upon an exercise of
this option shall be  subject to the Optionee’s satisfaction of all applicable
Federal, state and local income, excise, employment and  other tax withholding
requirements (“tax obligations”).  The  Optionee may satisfy any such tax
obligations in any of the  manners provided in Section 3(b)(i), (ii) or (iv) above for
payment of the purchase price, or any combination thereof. 

     4.
            Restrictions on Disposition of Option Shares.  The  provisions of Section 3(g) of the
Employment Agreement shall  apply to this option. 

     5.
            Nontransferability of Option.  This option is  personal and no rights granted hereunder
may be transferred,  assigned, pledged or hypothecated in any way (whether by  operation
of law or otherwise) nor shall any such rights be  subject to execution, attachment or
similar process, except  that this option may be transferred in whole or in part (x)  by
will or the  

27 

laws of descent
and distribution or (y)  gratuitously to any Family Member who agrees to be bound by  the
provisions of this Stock Option Agreement.  For purposes  of clause (y) of the preceding
sentence, “Family Member” shall mean “family member” as such term is
used as of the  Grant Date in Section A1(a)(5) of the General Instructions  to SEC Form
S-8, together with any entity described in  clause (ii) of such Section A1(a)(5).  Any
Person to whom  this option has been transferred in whole or in part in  accordance with
the first sentence of this Section 5 shall,  to the extent of the transfer, succeed to
the rights, and  assume the obligations, of the Optionee under Sections 2, 3,  5 and 6 of
this Stock Option Agreement, except that such  Person may not transfer this option (in
whole or in part)  pursuant to clause (y) of such sentence to any Person to  whom the
original Optionee would not have been permitted to  transfer this option (in whole or in
part).  The Optionee  shall give notice to the Company of any transfer of this  option,
in whole or in part, pursuant to clause (y) of the  first sentence of this Section 5. 

     6.
            Adjustments.  In the event that, at any time after  the Grant Date, any merger,
consolidation, reorganization,  recapitalization, spin-off, split-up, combination,
modification of securities, exchange of securities,  liquidation, dissolution, share
split, share dividend, other  distribution of securities or other property in respect of
Shares or other securities (other than ordinary-course cash  dividends), or other change
in corporate structure or  capitalization affecting the rights or value of securities  of
any class then subject to this option occurs, appropriate  adjustment(s) shall promptly
be made in the number and/or  kind of securities subject to this option and/or in the
Exercise Price  and/or in other terms and conditions of this  option, and/or appropriate
provision(s) shall promptly be  made for supplemental distributions of cash, securities
and/or other property, so as to avoid dilution or  enlargement of the rights of the
Optionee and the value  represented by this option.  If an event occurs that may  require
an adjustment (or other action) pursuant to this  Section 6, the Company shall
promptly deliver to the  Optionee a certificate, signed by an officer of the Company,
setting forth in reasonable detail (x) the event in question  and (y) either the
adjustment (or other action) being  implemented and the method by which such adjustment
(or  other action) was calculated or determined or the reasons  why the Company believes
no adjustment (or other action) is  needed. 

     7.
Miscellaneous. 

          (a)
This Stock Option Agreement, together with the  Plan, contains the entire understanding
and agreement  between the Parties concerning the specific subject matter  hereof.  It
shall be governed, construed and enforced in  accordance with its express terms, and
otherwise in  accordance with the laws of the State of Delaware without  regard to
principles of conflict of laws. 

          (b)
Sections 4(a), 11, 12, 13 (first sentence only),  14(b), 14(c), 16(a) and 16(d) of the
Employment Agreement  (relating, respectively, to representations, notices,  dispute
resolution, severability, amendment and waiver,  inconsistencies, references and
headings) shall be deemed  incorporated herein in full, with the references to the  “Agreement” in
such Sections  

28 

being treated
as references to  this Stock Option Agreement and the references to “you” in
such Sections being treated as references to the original  Optionee. 

          (c)
Nothing contained in this Stock Option Agreement  shall be construed or deemed by any
Person under any  circumstances to bind the Company to continue the employment  of the
Optionee for any particular period of time. 

          (d)
This Stock Option Agreement may be executed in  counterparts, each of which shall be
deemed an original and  all of which together shall be deemed to be one and the same
instrument.  Signatures delivered by facsimile shall be  effective for all purposes. 

Grant Date:
March  31, 2006 

	 	 GENTA,
INCORPORATED
	 	 	 
	 	By:	/s/ Daniel Von Hoff, M.D.
	 	 	

	 	Name: 	Daniel
Von
Hoff,
M.D.
	 	Title:	
      Chairman of the Compensation Committee of the Board
	 	 Date:	 March
31,
2006

	ACCEPTED
      AND AGREED	 
	 	 
	OPTIONEE	 
	 	 
	/s/ Raymond P. Warrell,
      Jr., M.D.	 
	
	 
	Dr. Raymond P. Warrell,
      Jr., M.D.	 
	Date: March 31, 2006	 

29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]